Please login to the form below

Not currently logged in
Email:
Password:

Sigma-Tau Pharmaceuticals appoints Dave Lemus chief operating officer

He takes over from Gregg Lapointe who has resigned

Dave Lemus has been appointed chief operating officer at Sigma-Tau Pharmaceuticals.

He joined the US rare diseases company in July 2011 as VP, finance and in his new role he takes over from Gregg Lapointe who has resigned.

President of Sigma-Tau Pharmaceuticals Professor Trevor Jones said: "We are delighted to appoint Dave to lead our efforts to expand the world-class rare disease business we have established in the US.

“Dave brings a wealth of relevant pharmaceutical and biotech experience from both the US and Europe. His appointment will serve to further strengthen our unwavering mission to serve the needs of rare disease patients."

Prior to joining Sigma-Tau Lemus was chief financial officer at German biotech company MorphoSys, where he launched Germany's first-ever biotechnology IPO in 1999.

Before this he held a variety of senior management roles at Hoffmann-La Roche and Lindt in Switzerland.

12th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics